Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles

Biomaterials

Volumn 28, Issue 12, 2007, Pages 2137-2146

  Lee, Mi Kyung ^a,b   Lim, Soo Jeong ^c   Kim, Chong Kook ^a  

^a Seoul National University   (South Korea)

^b Woosuk University   (South Korea)

^c Sejong University   (South Korea)

Author keywords

Cancer; Drug delivery; Paclitaxel; Solid lipid nanoparticles

Indexed keywords

CYTOTOXICITY; PACLITAXEL LOADING; SOLID LIPID NANOPARTICLES (SLN); ZETA POTENTIALS;

CONTROLLED DRUG DELIVERY; NANOSTRUCTURED MATERIALS; PHOSPHOLIPIDS; SCANNING ELECTRON MICROSCOPY; TOXICITY; TUMORS;

CYTOLOGY;

CREMOPHOR; PACLITAXEL; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; SOLID LIPID NANOPARTICLE; STABILIZING AGENT; TRIMYRISTIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL STRAIN MCF 7; COLUMN CHROMATOGRAPHY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; STEREOCHEMISTRY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; HUMANS; LIPIDS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; OVARIAN NEOPLASMS; PACLITAXEL; PARTICLE SIZE;

EID: 33846677328     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2007.01.014     Document Type: Article

References (24)

1. Hawkins M.J. New anticancer agents: taxol, camptothecin analogs, and anthrapyrazoles. Oncology 6 (1992) 17-23
2. Holmes F.A., Walters R.S., Theriault R.L., Forman A.D., Newton L.K., Raber M.N., et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83 (1991) 1797-1805
3. Markman M. Taxol: an important new drug in the management of epithelial ovarian cancer. Yale J Biol Med 64 (1991) 583-590
4. Sung F.L., Poon T.C., Hui E.P., Ma B.B., Liong E., To K.F., et al. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells. In Vivo 19 (2005) 237-245
5. Trissel L.A., Xu Q.A., and Gilbert D.L. Compatibility and stability of paclitaxel combined with doxorubicin hydrochloride in infusion solutions. Ann Pharmacother 32 (1998) 1013-1016
6. Zhang Y., Xu Q.A., Trissel L.A., Gilbert D.L., and Martinez J.F. Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions. Ann Pharmacother 31 (1997) 1465-1470
7. Allen T.M. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56 (1998) 747-756
8. Tarr B.D., Sambandan T.G., and Yalkowsky S.H. A new parenteral emulsion for the administration of taxol. Pharm Res 4 (1987) 162-165
9. Sampedro F., Partika J., Santalo P., Molins-Pujol A.M., Bonal J., and Perez-Soler R. Liposomes as carriers of different new lipophilic antitumour drugs: a preliminary report. J Microencapsul 11 (1994) 309-318
10. Sharma A., and Straubinger R.M. Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm Res 11 (1994) 889-896
11. Siekmann B., and Westesen K. In: Benita S. (Ed). Submicron emulsions in drug targeting and delivery (1998), Horwood Academic Publishers, New York 205-218
12. Stewart J.L.M. Calorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 104 (1959) 10-14
13. Müller R.H., and Heinemann S. Fat emulsions for parenteral nutrition II: characterisation and physical long-term stability of lipofundin MCT LCT. Clin Nutr 11 (1992) 223-272
14. Schwarz C., Mehnert W., Lucks J.S., and Müller R.H. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Controlled Release 30 (1994) 83-96
15. Westesen K., and Siekmann B. Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles. Int J Pharm 151 (1997) 35-45
16. Westesen K., and Wehler T. Physicochemical characterization of a model intravenous oil-in-water emulsion. J Pharm Sci 81 (1992) 777-786
17. Winternitz C.I., Jackson J.K., Oktaba A.M., and Burt A.M. Development of a polymeric surgical paste formulation for taxol. Pharm Res 13 (1996) 368-375
18. Lee M.K., Choi L., Kim M.H., and Kim C.K. Pharmacokinetics and organ distribution of cyclosporin A incorporated in liposomes and mixed micelles. Int J Pharm 191 (1999) 87-93
19. Park K.M., Lee M.K., Hwang K.J., and Kim C.K. Phospholipid-based microemulsions of flurbiprofen by the spontaneous emulsification process. Int J Pharm 183 (1999) 145-154
20. Maincent RBaP. In: Lieberman H.A., and MMRaGSB (Eds). Pharmaceutical dosage forms: disperse systems (1998), Marcel Dekker, New York 87-127
21. Cattel L., Ceruti M., and Dosio F. From conventional to stealth liposomes: a new Frontier in cancer chemotherapy. J Chemother 16 (2004) 94-97
22. Müller R.H., Rühl D., and Runge S.A. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm 144 (1996) 115-121
23. Fonseca C., Simoes S., and Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Controlled Release 83 (2002) 273-286
24. Leroux J.C. In: Benita S. (Ed). Microencapsulation: methods and industrial Applications (1996), Marcel Dekker, New York